Diagnostic Center | October 27, 2022
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Results reinforce commitment to next-generation oral SERD development programme
Results reinforce commitment to next-generation oral SERD development programme
The company has reported total income of Rs.826.40 crores for FY 2020-21
Subscribe To Our Newsletter & Stay Updated